Inventor · disambiguated record
Qinghua Meng
Also filed as: MENG QINGHUA
6 granted patents·16 pending applications·19 citations·filing 2010–2024
78Inventor score
Top patents by PatentIndex Score
22 records- 0194US11926626B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2022·Granted Mar 12, 2024·7 cites·23 claims
- 0294US11492365B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2022·Granted Nov 8, 2022·6 cites·15 claims
- 0393US12221442B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2024·Granted Feb 11, 2025·3 cites·4 claims
- 0492US11897851B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2023·Granted Feb 13, 2024·3 cites·5 claims
- 0582US2025115606A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2024·Application pending·0 cites
- 0675US2023071840A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2022·Application pending·0 cites
- 0771US11926643B2Heterocyclic GLP-1 agonistsGASHERBRUM BIO INC·Filed 2022·Granted Mar 12, 2024·0 cites·20 claims
- 0861US2023295154A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 0960US2025250269A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1060US2025206757A15,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetesGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1160US2025109148A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1258US2025145596A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1358US2025177362A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 1458US2024366639A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2022·Application pending·0 cites
- 1555US2023391760A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 1653US2024083886A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 1753US2023322771A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 1850US2023165846A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2021·Application pending·0 cites
- 1949US2025188103A1Heterocyclic glp-1 agonistsGASHERBRUM BIO INC·Filed 2023·Application pending·0 cites
- 2040US10005731B2Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseasesGLAXO GROUP LTD·Filed 2013·Granted Jun 26, 2018·0 cites·19 claims
- 2132US2012101123A1CompoundsLI CHENGYONG·Filed 2010·Application pending·0 cites
- 2227US2012101134A15-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonistsDENG GUANGHUI·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Qinghua Meng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →